Cargando…
Metabolomic Analysis of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
Background: In the US in 2021, 76,080 kidney cancers are expected and >80% are renal cell carcinomas (RCCs). Along with excess fat, metabolic dysfunction is implicated in RCC etiology. To identify RCC-associated metabolites, we conducted a 1:1 matched case–control study nested within the Prostate...
Autores principales: | McClain, Kathleen M., Sampson, Joshua N., Petrick, Jessica L., Mazzilli, Kaitlyn M., Gerszten, Robert E., Clish, Clary B., Purdue, Mark P., Lipworth, Loren, Moore, Steven C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785244/ https://www.ncbi.nlm.nih.gov/pubmed/36557227 http://dx.doi.org/10.3390/metabo12121189 |
Ejemplares similares
-
Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016) -
Metabolomics: an emerging but powerful tool for precision medicine
por: Clish, Clary B.
Publicado: (2015) -
A Metabolomics Analysis of Postmenopausal Breast Cancer Risk in the Cancer Prevention Study II
por: Moore, Steven C., et al.
Publicado: (2021) -
Proteomic and Metabolomic Correlates of Healthy Dietary Patterns: The Framingham Heart Study
por: Walker, Maura E., et al.
Publicado: (2020) -
Metabolomics of renal venous plasma from individuals with unilateral renal artery stenosis and essential hypertension
por: Rhee, Eugene P., et al.
Publicado: (2015)